RenovoRx, Inc. Q3 FY2025 earnings call

• TAMP Platform: RenovoRx's preparatory transarterial microperfusion therapy (TAMP) platform has early clinical adoption from academic medical centers, NCI-designated cancer centers, and large community hospitals, with multidisciplinary engagement expanding. • RenovoCath Commercial: Year-to-date revenue was ~$900,000; expanded from 5 to 14 approved centers to purchase RenovoCath, with 5 centers making repeat orders; hired Phil Stockton as Senior Director of Sales and Market Development, and plans to add regional sales managers and a marketing director. • Clinical Programs: Post-marketing registry study launched in July is progressing, with first patient procedure initiated; Phase III TIGER PACT trial enrollment expected to complete in early 2026, final data in 2027, and Data Monitoring Committee recommended continuing the study. • Scientific Advisory Board: Strengthened with addition of recognized surgeon Dr. Timothy Donahue and interventional oncologist Dr. Thierry De Baere.

For the third quarter ended 09/30/2025, RenovoRx reported revenues of approximately $266,000, driven by RenovoCath sales. Year-to-date revenue through the end of Q3 was approximately $900,000. RenovoCath's revenue contribution comes from its commercial sales of the medical device, with early adoption and growing interest from various cancer centers.

• Cash Position: As of 09/30/2025, RenovoRx had over $10 million in cash and cash equivalents; cash on hand is expected to fund RenovoCath commercial scale-up and continued progress of Phase III TIGER PACT trial into 2026. • Phase III Trial: Enrollment in TIGER PACT is expected to complete in early 2026, final data anticipated in 2027; DMC's recommendation expresses confidence in potential positive outcome of the trial.

• International Expansion: While positive reception exists, focus is currently on the U.S. with plans to explore international market later. • Supply Chain: While supply chain with U.S.-based contract manufacturer is strong, potential global macro factors could pose risks though currently insulated as components are sourced in the U.S.

Q: Ed Woo asked about going international and supply chain.

A: Shaun Bagai said they've focused on the U.S. for now due to favorable reimbursement and large interest there, but will explore international in the future; supply chain is with a U.S.-based contract manufacturer and components are sourced in the U.S.

Q: Charles Wallace asked about fruits of new sales director hire and commercial focus.

A: Shaun Bagai said new hires help in sales strategy, with focus on increasing breadth and footprint; 24 centers have requested quotes for RenovoCath, and enrollment in Phase III TIGER PACT is expected to complete in early 2026, final data in 2027